Teva Pharmaceutical/$TEVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Teva Pharmaceutical
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Ticker
$TEVA
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Tel Aviv, Israel
Employees
37,000
ISIN
US8816242098
Website
TEVA Metrics
BasicAdvanced
$19B
-
-$1.14
0.63
-
Price and volume
Market cap
$19B
Beta
0.63
52-week high
$22.80
52-week low
$12.47
Average daily volume
11M
Financial strength
Current ratio
1.033
Quick ratio
0.455
Long term debt to equity
263.487
Total debt to equity
270.203
Interest coverage (TTM)
3.52%
Profitability
EBITDA (TTM)
4,452
Gross margin (TTM)
49.16%
Net profit margin (TTM)
-7.74%
Operating margin (TTM)
20.59%
Effective tax rate (TTM)
-154.83%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
5.31%
Return on equity (TTM)
-19.11%
Valuation
Price to revenue (TTM)
1.145
Price to book
3.07
Price to tangible book (TTM)
-1.43
Price to free cash flow (TTM)
24.861
Free cash flow yield (TTM)
4.02%
Free cash flow per share (TTM)
67.42%
Growth
Revenue change (TTM)
3.82%
Earnings per share change (TTM)
167.96%
3-year revenue growth (CAGR)
2.22%
10-year revenue growth (CAGR)
-1.96%
3-year earnings per share growth (CAGR)
27.06%
10-year earnings per share growth (CAGR)
-9.81%
What the Analysts think about TEVA
Analyst ratings (Buy, Hold, Sell) for Teva Pharmaceutical stock.
Bulls say / Bears say
Teva's innovative drug Austedo, used for treating Huntington's disease, has shown strong performance with a 32% increase in quarterly sales to $407 million, leading the company to raise its revenue forecast for the drug by $100 million to approximately $1.6 billion for 2024. (reuters.com)
The company has announced a strategic plan to achieve approximately $700 million in net cost savings by 2027, with about half of these savings expected to be realized by 2026, aiming for an adjusted operating margin of 30% by 2027. (finviz.com)
Teva is expanding its biosimilar portfolio with plans to launch six biosimilar drugs by 2027, including Simlandi, a biosimilar of AbbVie's Humira, which is set to launch in the coming weeks following FDA approval in February 2024. (reuters.com)
Teva is currently in negotiations to settle a U.S. Department of Justice lawsuit alleging the company used charities to pay illegal kickbacks to boost sales of its multiple sclerosis drug, Copaxone, with potential damages amounting to $10 billion. (reuters.com)
The company has agreed to a $750 million settlement with the Israel Tax Authority to resolve tax disputes for the years 2008 to 2020, with payments scheduled from 2024 to 2029, potentially impacting its financial flexibility. (reuters.com)
Teva's 2025 earnings outlook has fallen short of analyst expectations, with forecasted revenue of $16.8 to $17.4 billion and EPS of $2.35-$2.65, compared to analysts' expectations of $17.1 billion in revenue and EPS of $2.76. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TEVA Financial Performance
Revenues and expenses
TEVA Earnings Performance
Company profitability
TEVA News
AllArticlesVideos
Teva Releases Q2 2025 Aide Memoire
GlobeNewsWire·5 days ago
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
GlobeNewsWire·6 days ago
Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Teva Pharmaceutical stock?
Teva Pharmaceutical (TEVA) has a market cap of $19B as of July 01, 2025.
What is the P/E ratio for Teva Pharmaceutical stock?
The price to earnings (P/E) ratio for Teva Pharmaceutical (TEVA) stock is 0 as of July 01, 2025.
Does Teva Pharmaceutical stock pay dividends?
No, Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders as of July 01, 2025.
When is the next Teva Pharmaceutical dividend payment date?
Teva Pharmaceutical (TEVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Teva Pharmaceutical?
Teva Pharmaceutical (TEVA) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.